# Effect of Copanlisib on Metformin Pharmacokinetics and Pharmacodynamics

> **NCT03655301** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 13 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Copanlisib (Aliqopa, BAY80-6946)
- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT03655301
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-11
- **Primary completion:** 2018-11-12
- **Final completion:** 2019-02-12
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2020-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03655301

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03655301, "Effect of Copanlisib on Metformin Pharmacokinetics and Pharmacodynamics". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT03655301. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*